Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
about
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC CellsConcurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer TypesClinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations.Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma.Comprehensive Molecular Analysis of NSCLC; Clinicopathological AssociationsHigh metallothionein predicts poor survival in glioblastoma multiforme.Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis.Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patientsPIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutationsAssessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer.Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma.Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.Progression inference for somatic mutations in cancer.CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons: Rapid way to detect EGFR and KRAS mutations.Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma.Tumour-to-tumour metastasis from papillary thyroid carcinoma with BRAF mutation to lung adenocarcinoma with EGFR mutation: the utility of mutation-specific antibodies.Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer.KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Clinical mutational profiling of 1006 lung cancers by next generation sequencing.[Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer].Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.Genomic alterations of ground-glass nodular lung adenocarcinoma.Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients
P2860
Q28551045-73E35E3F-6BD5-4880-A393-176B170E0C46Q33648747-31F6F50C-8013-4EFA-B148-B09F22DF5F7FQ33673752-6FCBBB62-2AE4-4603-ADA4-38079EFC8252Q34347975-126BD0C4-67DF-4419-9E80-8CD1C4F9B65AQ34658204-8746E66B-B808-453C-B9E3-12A2C580251AQ35663416-C657D5BA-B912-4E79-9096-B1C3332692A9Q35712214-3B1CF9E5-DB11-487D-B1F7-38CE3615F27DQ35817939-1324F7C7-DDC2-4B3F-B578-E54D37FC6AB1Q35824117-45C59897-2F4F-45B0-B040-DD46BB66D158Q36184824-3DBE49F6-615B-4691-8A12-4E3AD78FBC93Q36378189-2AE5020A-3206-4D36-87E3-300BE44DECF2Q36477762-CF1B4B60-98C8-4E32-B188-01783CCD63B7Q36946796-2D7C8D6A-AF5B-41A9-AE2C-E74F8BD2DBC1Q36946809-7383AE9E-0D15-4DC7-8945-A886EC974C0CQ37269159-D69A9B90-03B0-40E0-9437-B6076D0DBB4DQ37353957-89B8AA58-6116-4C0B-A35D-28206DA9ADC2Q37373041-71CBAEA4-CAFD-436D-9EEA-DAF67C02D7F7Q37580410-DBD343C2-F027-4578-912E-A7F421E1F281Q37619679-FC14D3BC-C0CD-4DF1-9C2A-038E282D48E4Q37641681-75AB08C8-E471-4F24-B181-5DB6A1076FB1Q37709050-B32ECD95-952C-4350-A224-0F80F7C2914EQ38358410-560AF16B-9F35-4125-9DEB-3BC626DC55ECQ38738104-E6064BB0-CB12-436D-8A45-E06DFEA1C6BDQ38793244-23313F16-216E-4955-86A9-67B57BEFB8C4Q38924458-E0418D1F-8B0B-49BF-9716-BAEA13AA2CF7Q39129178-69BB0AAA-7661-4B23-8605-FBBB31DC8CCEQ40530427-27093169-82AD-4BB1-A537-0AD006BB3D17Q40812047-427C60D2-06B2-4065-80A1-3944C839FBA7Q41037400-5E8F6E87-16F3-49DB-8703-5DB6CE7387ECQ42175731-B0EB4951-210A-4F63-9413-488689763519Q45913413-B37ED7C1-5F56-4958-9D7F-D10B4138C947Q47146662-95B464A5-EC5B-41E8-95A5-22C9828FD3BAQ47848473-0D780499-E1D4-45D6-9513-C6CC989DEE2DQ49468021-82292EA6-D17A-43BB-929C-0FF60ABE5AF6Q49887897-61849888-460E-4A62-A84F-E9BD66173BA6Q49930825-97E92EA6-938E-4B40-B7C0-F56DAB87B8CEQ53565079-4C672818-B697-4746-84B7-84972A816C96Q53623110-12B5C16B-ED49-4373-BC6A-79DD0F28EE58Q54209531-7B01777E-6942-4B10-BC4A-CCC4A7F04FB3Q57174616-37032AE2-D53B-4C68-A043-0E5BD58628C5
P2860
Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Coexistence of EGFR with KRAS, ...... ing from 5125 Chinese cohorts.
@ast
Coexistence of EGFR with KRAS, ...... ing from 5125 Chinese cohorts.
@en
type
label
Coexistence of EGFR with KRAS, ...... ing from 5125 Chinese cohorts.
@ast
Coexistence of EGFR with KRAS, ...... ing from 5125 Chinese cohorts.
@en
prefLabel
Coexistence of EGFR with KRAS, ...... ing from 5125 Chinese cohorts.
@ast
Coexistence of EGFR with KRAS, ...... ing from 5125 Chinese cohorts.
@en
P2093
P2860
P356
P1476
Coexistence of EGFR with KRAS, ...... ing from 5125 Chinese cohorts.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2014.210
P407
P577
2014-04-17T00:00:00Z
P5875
P6179
1050939993